- Home
- PHUN vs KYNB Comparison
PHUN vs KYNB Comparison
Compare PHUN & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | KYNB |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 31.9M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | KYNB |
|---|---|---|
| Price | $1.72 | $7.00 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 91.8K | 33.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $95.95 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $6.67 |
| 52 Week High | $3.88 | $9.58 |
Technical Indicators
Market Signals| Indicator | PHUN | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 45.04 |
| Support Level | $1.60 | $7.11 |
| Resistance Level | $2.04 | $7.65 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 52.05 | 45.87 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.